Despite progress, clinical translation of tissue engineering (TE) products/technologies is limited. A significant effort is underway to develop biomaterials and cells through a minimally modified process for clinical translation of TE products. Recently, bone marrow aspirate (BMA) was identified as an autologous source of cells for TE applications and is currently being tested in clinical therapies, but the isolation methods need improvement to avoid potential for contamination and increase progenitor cell yield. To address these issues, we reproducibly processed human peripheral blood (PB) and BMA to develop autologously derived biomaterials and cells. We demonstrated PB-derived biomaterial/gel cross-linking and fibrin gel formation with varied gelation times as well as biocompatibility through support of human bone marrow-derived stem cell survival and growth in vitro. Next, we established a plastic culture-free process that concentrates and increases the yield of CD146⁺/CD271⁺ early mesenchymal progenitor cells in BMA (concentrated BMA [cBMA]). cBMA exhibited increased colony formation and multipotency (including chondrogenic differentiation) in vitro compared with standard BMA. PB-derived gels encapsulated with cBMA also demonstrated increased cell proliferation and enhanced mineralization when assessed for bone TE in vitro. This strategy can potentially be developed for use in any tissue regeneration application; however, bone regeneration was used as a test bed for this study.

中文翻译：

---

自体衍生生物材料和干细胞用于骨组织工程的评估。

尽管取得了进展，但组织工程 (TE) 产品/技术的临床转化是有限的。一项重大的努力正在进行中，通过对 TE 产品进行临床转化的最小修改过程来开发生物材料和细胞。最近，骨髓抽吸物 (BMA) 被确定为用于 TE 应用的自体细胞来源，目前正在临床治疗中进行测试，但分离方法需要改进，以避免潜在的污染并增加祖细胞产量。为了解决这些问题，我们对人类外周血 (PB) 和 BMA 进行了可重复处理，以开发自体衍生的生物材料和细胞。体外。接下来，我们建立了一种无塑料培养工艺，可在 BMA（浓缩 BMA [cBMA]）中浓缩并提高 CD146 ⁺ /CD271 ⁺早期间充质祖细胞的产量。与标准 BMA 相比，cBMA在体外表现出增加的集落形成和多能性（包括软骨形成分化）。在体外评估骨 TE 时，用 cBMA 封装的 PB 衍生凝胶也显示出增加的细胞增殖和增强的矿化。这种策略有可能被开发用于任何组织再生应用；然而，骨再生被用作本研究的试验台。